12-LOX和SEPT7及RhoA蛋白与神经胶质瘤患者临床分期与预后的相关性研究  

The relationship between the expression of 12-LOX,SEPT7 and RhoA and clinical stages and prognosis in glioma patients

作　　者：李志超[1] 王亚明[1] 皇甫罗锴[1] 张雷鸣[1] 

机构地区：[1]中国人民解放军海军总医院神经外科,北京100048

出　　处：《临床和实验医学杂志》2016年第10期961-964,共4页Journal of Clinical and Experimental Medicine

摘　　要：目的对12-脂氧化酶脂加氧酶(12-LOX)和胞裂蛋白7(SEPT7)及Ras同源蛋白A(Rho A)蛋白与神经胶质瘤患者临床分期与预后的相关性进行分析,为临床诊断和治疗提供参考。方法对2010年5月至2015年11月期间诊治的神经胶质瘤患者进行研究,检测不同临床分期患者血清中12-LOX和SEPT7及Rho A的表达,并分析不同表达强度患者的预后。以同期健康体检者120例为对照组。结果与对照组相比,神经胶质瘤组患者12-LOX及p12-LOX、SETT7、S100A4、Rho A和ROCK1/2蛋白表达水平均明升高,且与其临床分期具有明显的相关性,Ⅲ期和Ⅳ患者的表达水平明显高于Ⅰ期和Ⅱ期患者(P<0.05);12-LOX、SEPT7和Rho A蛋白表达水平与神经胶质瘤患者预后密切相关,且上述蛋白的表达越高,神经胶质瘤患者的预后越差。结论 12-LOX、SEPT7和Rho A及其蛋白是神经胶质瘤临床分期诊断的标志物,且与患者的预后密切相关。Objective The present study tried to prove the relationship between the expression of 12- LOX,SEPT7 and RhoA and clinical stages and prognosis in glioma patients. Methods 180 cases of glioma patients from Mar 2010 to Nov 2015 were enrolled in this research. The serum content of 12- LOX,p12- LOX,SETT7,S100A4,RhoA and ROCK1 /2 were assayed in patients of each group. The prognosis of the glioma patients were assayed based on the expression of 12- LOX,SEPT7 and RhoA. 120 cases of normal subjects were taken as control in this research. Results The results showed that the expression of 12- LOX,p12- LOX,SETT7,S100A4,RhoA and ROCK1 /2 increased greatly with the development of glioma. The results also revealed that the 12- LOX,SEPT7 and RhoA expression were negatively related with the prognosis of the glioma patients. Conclusion 12- LOX,SEPT7 and RhoA expression can be taken as indicators for the clinical stage of glioma and are negatively related with the prognosis of the patients.

关 键 词：神经胶质瘤 12-脂氧化酶脂加氧酶 胞裂蛋白7 RHOA蛋白 临床分期 预后 

分 类 号：R739.41[医药卫生—肿瘤]